Product References
Targeting BRD3 eradicates nuclear TYRO3-induced colorectal cancer metastasis.
Science advances
Hsu PL,Chien CW,Tang YA,Lin BW,Lin SC,Lin YS,Chen SY,Sun HS,Tsai SJ
Fri Apr 14 00:00:00 EDT 2023
The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage.
Journal of neuroinflammation
Zhu X,Liu W,Tang X,Chen Y,Ge X,Ke Q,Liang X,Gan Y,Zheng Y,Zou M,Deng M,Liu Y,Li DW,Gong L
Mon May 22 00:00:00 EDT 2023
BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Cancer biology & therapy
Ma L,Wang J,Zhang Y,Fang F,Ling J,Chu X,Zhang Z,Tao Y,Li X,Tian Y,Li Z,Sang X,Zhang K,Lu L,Wan X,Chen Y,Yu J,Zhuo R,Wu S,Lu J,Pan J,Hu S
Sat Dec 31 00:00:00 EST 2022
The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma.
Journal of immunology research
Jia SQ,Zhuo R,Zhang ZM,Yang Y,Tao YF,Wang JW,Li XL,Xie Y,Li G,Wu D,Chen YL,Yu JJ,Feng CX,Li ZH,Zhou RF,Yang RD,Yang PC,Zhou B,Wan XM,Wu YM,Jiao WY,Zhou NN,Fang F,Pan J
Tue Nov 29 00:00:00 EST 2022
Super-enhancer profiling identifies novel critical and targetable cancer survival gene LYL1 in pediatric acute myeloid leukemia.
Journal of experimental & clinical cancer research : CR
Fang F,Lu J,Sang X,Tao YF,Wang JW,Zhang ZM,Zhang YP,Li XL,Xie Y,Wu SY,Chu XR,Li G,Wu D,Chen YL,Yu JJ,Jia SQ,Feng CX,Tian YY,Li ZH,Ling J,Hu SY,Pan J
Sat Jul 16 00:00:00 EDT 2022
A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells.
Pathology oncology research : POR
Zhang K,Gao L,Wang J,Chu X,Zhang Z,Zhang Y,Fang F,Tao Y,Li X,Tian Y,Li Z,Sang X,Ma L,Lu L,Chen Y,Yu J,Zhuo R,Wu S,Pan J,Hu S
Wed Nov 09 00:00:00 EST 2022
A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.
Nature communications
Yamanaka S,Horiuchi Y,Matsuoka S,Kido K,Nishino K,Maeno M,Shibata N,Kosako H,Sawasaki T
Mon Jan 10 00:00:00 EST 2022
An inhibitor of BRD4, GNE987, inhibits the growth of glioblastoma cells by targeting C-Myc and S100A16.
Cancer chemotherapy and pharmacology
Ma L,Li G,Yang T,Zhang L,Wang X,Xu X,Ni H
Thu Dec 01 00:00:00 EST 2022
BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Journal of immunology research
Sang X,Zhang Y,Fang F,Gao L,Tao Y,Li X,Zhang Z,Wang J,Tian Y,Li Z,Yao D,Wu Y,Chu X,Zhang K,Ma L,Lu L,Chen Y,Yu J,Zhuo R,Wu S,Zhang Z,Pan J,Hu S
Mon Aug 15 00:00:00 EDT 2022
BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma.
Biochemical and biophysical research communications
Zhang X,Guo X,Zhuo R,Tao Y,Liang W,Yang R,Chen Y,Cao H,Jia S,Yu J,Liao X,Li X,Fang F,Li G,Wu D,Xu Y,Li Z,Pan J,Wang J
Sat May 14 00:00:00 EDT 2022
BRD4 inhibitor GNE987 exerts anti-cancer effects by targeting super-enhancers in neuroblastoma.
Cell & bioscience
Chen YL,Li XL,Li G,Tao YF,Zhuo R,Cao HB,Jiao WY,Li ZH,Zhu ZH,Fang F,Xie Y,Liao XM,Wu D,Wang HR,Yu JJ,Jia SQ,Yang Y,Feng CX,Yang PC,Fei XD,Wang JW,Xu YY,Qian GH,Zhang ZM,Pan J
Fri Mar 18 00:00:00 EDT 2022
Cancer Selective Target Degradation by Folate-Caged PROTACs.
Journal of the American Chemical Society
Liu J,Chen H,Liu Y,Shen Y,Meng F,Kaniskan HÜ,Jin J,Wei W
Wed May 19 00:00:00 EDT 2021
ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways.
Frontiers in oncology
Liao X,Qian X,Zhang Z,Tao Y,Li Z,Zhang Q,Liang H,Li X,Xie Y,Zhuo R,Chen Y,Jiang Y,Cao H,Niu J,Xue C,Ni J,Pan J,Cui D
Thu Apr 28 00:00:00 EDT 2022
BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
Oncogene
Ni M,Li J,Zhao H,Xu F,Cheng J,Yu M,Ke G,Wu X
Thu Apr 01 00:00:00 EDT 2021
BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes.
Cancer cell international
Wu S,Jiang Y,Hong Y,Chu X,Zhang Z,Tao Y,Fan Z,Bai Z,Li X,Chen Y,Li Z,Ding X,Lv H,Du X,Lim SL,Zhang Y,Huang S,Lu J,Pan J,Hu S
Thu Apr 22 00:00:00 EDT 2021
Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.
Nature communications
Wang W,Tang YA,Xiao Q,Lee WC,Cheng B,Niu Z,Oguz G,Feng M,Lee PL,Li B,Yang ZH,Chen YF,Lan P,Wu XJ,Yu Q
Wed Jul 21 00:00:00 EDT 2021
Light-induced control of protein destruction by opto-PROTAC.
Science advances
Liu J,Chen H,Ma L,He Z,Wang D,Liu Y,Lin Q,Zhang T,Gray N,Kaniskan HÜ,Jin J,Wei W
Sat Feb 01 00:00:00 EST 2020
PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc.
Frontiers in oncology
Li Z,Lim SL,Tao Y,Li X,Xie Y,Yang C,Zhang Z,Jiang Y,Zhang X,Cao X,Wang H,Qian G,Wu Y,Li M,Fang F,Liu Y,Fu M,Ding X,Zhu Z,Lv H,Lu J,Xiao S,Hu S,Pan J
Thu Dec 17 00:00:00 EST 2020
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.
Frontiers in oncology
Bian X,Wang X,Zhang Q,Ma L,Cao G,Xu A,Han J,Huang J,Lin W
Mon May 01 00:00:00 EDT 2023
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
Haematologica
Lim SL,Damnernsawad A,Shyamsunder P,Chng WJ,Han BC,Xu L,Pan J,Pravin DP,Alkan S,Tyner JW,Koeffler HP
Sat Jun 01 00:00:00 EDT 2019
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
Haematologica
Lim SL,Damnernsawad A,Shyamsunder P,Chng WJ,Han BC,Xu L,Pan J,Pravin DP,Alkan S,Tyner JW,Koeffler HP
Sat Jun 01 00:00:00 EDT 2019
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Nature medicine
Dai X,Gan W,Li X,Wang S,Zhang W,Huang L,Liu S,Zhong Q,Guo J,Zhang J,Chen T,Shimizu K,Beca F,Blattner M,Vasudevan D,Buckley DL,Qi J,Buser L,Liu P,Inuzuka H,Beck AH,Wang L,Wild PJ,Garraway LA,Rubin MA,Barbieri CE,Wong KK,Muthuswamy SK,Huang J,Chen Y,Bradner JE,Wei W
Fri Sep 01 00:00:00 EDT 2017
Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4.
Nature medicine
Dai X,Gan W,Li X,Wang S,Zhang W,Huang L,Liu S,Zhong Q,Guo J,Zhang J,Chen T,Shimizu K,Beca F,Blattner M,Vasudevan D,Buckley DL,Qi J,Buser L,Liu P,Inuzuka H,Beck AH,Wang L,Wild PJ,Garraway LA,Rubin MA,Barbieri CE,Wong KK,Muthuswamy SK,Huang J,Chen Y,Bradner JE,Wei W
Fri Sep 01 00:00:00 EDT 2017
The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis.
Nature communications
Shao Z,Zhang R,Khodadadi-Jamayran A,Chen B,Crowley MR,Festok MA,Crossman DK,Townes TM,Hu K
Mon Mar 07 00:00:00 EST 2016
The acetyllysine reader BRD3R promotes human nuclear reprogramming and regulates mitosis.
Nature communications
Shao Z,Zhang R,Khodadadi-Jamayran A,Chen B,Crowley MR,Festok MA,Crossman DK,Townes TM,Hu K
Mon Mar 07 00:00:00 EST 2016
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network.
Carcinogenesis
Zhang L,Deng T,Li X,Liu H,Zhou H,Ma J,Wu M,Zhou M,Shen S,Li X,Niu Z,Zhang W,Shi L,Xiang B,Lu J,Wang L,Li D,Tang H,Li G
Thu Apr 01 00:00:00 EDT 2010
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network.
Carcinogenesis
Zhang L,Deng T,Li X,Liu H,Zhou H,Ma J,Wu M,Zhou M,Shen S,Li X,Niu Z,Zhang W,Shi L,Xiang B,Lu J,Wang L,Li D,Tang H,Li G
Thu Apr 01 00:00:00 EDT 2010
